Trials / Unknown
UnknownNCT04158505
Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer
Real World Study on the Efficacy and Safety of Pyrotinib in the Treatment of HER2 Positive Breast Cancer: An Observational,Multi-center,Prospective Study (Real Pretty Study)
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,000 (estimated)
- Sponsor
- Chinese Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Non-Interventional Study will describe and analyze the clinical use of pyrotinib in clinical practice in the treatment of HER2 positive breast cancer in the real world.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | non-interventional | This prospective, observational study will be conducted according to each site's routine clinical practice |
Timeline
- Start date
- 2020-02-28
- Primary completion
- 2021-11-15
- Completion
- 2023-11-15
- First posted
- 2019-11-08
- Last updated
- 2020-04-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04158505. Inclusion in this directory is not an endorsement.